GENX.V GenixPharmaceucticals Corporation

Healthcare Pharmaceuticals TSX Venture Exchange
0.0150 CAD
Close of Nov 7, 2026
0.0200 0.0300
Market cap
CAD 918K
P/E
-
P/B
1.04x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Apr 2026.

Is GENX.V undervalued?

Graham number

The Graham number of GenixPharmaceucticals Corporation cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GenixPharmaceucticals Corporation fundamental analysis

No fundamental analysis for GenixPharmaceucticals Corporation yet.

GenixPharmaceucticals Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GenixPharmaceucticals Corporation

Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with a focus on nutraceuticals and pharmaceuticals in Canada. The company offers generic ophthalmic prescription products, ophthalmic nutraceutical formulations, and prescription generic drugs; ophthalmic OTC products; and eye ointments and drops. It also provides Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Rechlor, …

Full company profile